trial

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCTId NCT06585787
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 406 (estimated)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2026-11-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
406 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-09-26
Primary completion
2026-11-24
Eligibility
ALL · 55 Years · 90 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor

Sites

289 total
Chandler, United StatesGilbert, United StatesPhoenix, United StatesScottsdale, United StatesAnaheim, United StatesChino, United StatesLong Beach, United StatesLos Angeles, United StatesLos Angeles, United StatesOrange, United StatesOrange, United StatesPasadena, United States

Linked catalysts

1
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer — primary completion2026-11-24

Facts & assertions

4 sourced
Enrollment
406
Phase
PHASE3
Primary Completion Date
2026-11-24
Status
RECRUITING
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
indication
Alzheimer Disease
indication
Alzheimer Disease
indication
Psychotic Disorders
indication